Advertisement

AIDS and Behavior

, Volume 22, Issue 9, pp 2807–2814 | Cite as

A Comparison of Motivations for Marijuana Use in HIV-Positive and HIV-Negative Adults

  • Sheri L. ToweEmail author
  • Olivia E. Horton
  • Bianca Martin
  • Christina S. Meade
Original Paper

Abstract

While medicinal marijuana use is common among persons with HIV, it is not known whether persons with HIV are more motivated to use marijuana medically compared to HIV-negative counterparts. This study examined motivations for marijuana use in a sample of 94 HIV+ and HIV− adults. Participants used marijuana 21.27 days in the last 30 days on average. HIV+ participants reported using marijuana for medical reasons more often than HIV− participants, but HIV+ and HIV− participants did not differ in other domains. Problematic marijuana use was associated with motives, regardless of HIV status. Motives were associated with mental and physical health functioning, but there were no interactions between motivations and HIV status. Overall this study found that motivations were similar for HIV+ and HIV− participants. Future research including qualitative work to further understand motivations would benefit the field, as would research examining the effectiveness of marijuana in treating physical symptoms.

Keywords

Marijuana Cannabis Marijuana use motives HIV/AIDS Marijuana use disorders 

Notes

Acknowledgements

We thank all the men and women who participated in this study.

Funding

This study was funded by grants K23-DA028660, R03-DA035670, and T32-AI007392 from the United States National Institutes of Health. The NIH had no further role in study design, data collection, analysis and interpretation of data, writing the report, or in the decision to submit the paper for publication.

Compliance with Ethical Standards

Conflict of interest

All authors declare that they have no conflict of interest.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed Consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Center for Behavioral Health Statistics and Quality. Key substance use and mental health indicators in the United States: results from the 2015 National Survey on Drug Use and Health. Rockville: Substance Abuse and Mental Health Services Administration; 2016.Google Scholar
  2. 2.
    APA. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000.Google Scholar
  3. 3.
    D’Souza G, Matson P, Grady CD, et al. Medicinal and recreational marijuana use among HIV-infected women in the women’s interagency HIV cohort (WIHS), 1994–2010. J Acquir Immune Defic Syndr. 2012;61(5):618–26.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Mimiaga MJ, Reisner SL, Grasso C, et al. Substance use among HIV-infected patients engaged in primary care in the United States: findings from the Centers for AIDS research network of integrated clinical systems cohort. Am J Public Health. 2013;103(8):1457–67.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Gamarel KE, Brown L, Kahler CW, Fernandez MI, Bruce D, Nichols S. Prevalence and correlates of substance use among youth living with HIV in clinical settings. Drug Alcohol Depend. 2016;169:11–8.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Hartzler B, Carlini BH, Newville H, et al. Identifying HIV care enrollees at-risk for cannabis use disorder. AIDS Care. 2017;29(7):846–50.CrossRefPubMedGoogle Scholar
  7. 7.
    Okafor CN, Zhou Z, Burrell LE 2nd, et al. Marijuana use and viral suppression in persons receiving medical care for HIV-infection. Am J Drug Alcohol Abuse. 2017;43(1):103–10.CrossRefPubMedGoogle Scholar
  8. 8.
    Okafor CN, Cook RL, Chen X, et al. Trajectories of marijuana use among HIV-seropositive and HIV-seronegative MSM in the multicenter AIDS cohort study (MACS), 1984–2013. AIDS Behav. 2017;21(4):1091–104.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Crane HM, McCaul ME, Chander G, et al. Prevalence and factors associated with hazardous alcohol use among persons living with HIV across the US in the current era of antiretroviral treatment. AIDS Behav. 2017;21(7):1914–25.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Volkow ND, Baler RD, Compton WM, Weiss SR. Adverse health effects of marijuana use. New Engl J Med. 2014;370(23):2219–27.CrossRefPubMedGoogle Scholar
  11. 11.
    Lutge EE, Gray A, Siegfried N. The medical use of cannabis for reducing morbidity and mortality in patients with HIV/AIDS. Cochrane Database Syst Rev. 2013;2013:005175.Google Scholar
  12. 12.
    Haney M, Gunderson EW, Rabkin J, et al. Dronabinol and marijuana in HIV-positive marijuana smokers: caloric intake, mood, and sleep. J Acquir Immune Defic Syndr. 2007;45(5):545–54.CrossRefPubMedGoogle Scholar
  13. 13.
    Abrams DI, Jay CA, Shade SB, et al. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology. 2007;68(7):515–21.CrossRefPubMedGoogle Scholar
  14. 14.
    Ellis RJ, Toperoff W, Vaida F, et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology. 2009;34(3):672–80.CrossRefPubMedGoogle Scholar
  15. 15.
    National Conference of State Legislatures. State Medical Marijuana Laws. 2018. http://www.ncsl.org/research/health/state-medical-marijuana-laws. Accessed 10 Feb 2018.
  16. 16.
    Pacula RL, Jacobson M, Maksabedian EJ. In the weeds: a baseline view of cannabis use among legalizing states and their neighbours. Addiction. 2016;111(6):973–80.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Woolridge E, Barton S, Samuel J, Osorio J, Dougherty A, Holdcroft A. Cannabis use in HIV for pain and other medical symptoms. J Pain Symptom Manag. 2005;29(4):358–67.CrossRefGoogle Scholar
  18. 18.
    Furler MD, Einarson TR, Millson M, Walmsley S, Bendayan R. Medicinal and recreational marijuana use by patients infected with HIV. AIDS Patient Care STDs. 2004;18(4):215–28.CrossRefPubMedGoogle Scholar
  19. 19.
    Fogarty A, Rawstorne P, Prestage G, Crawford J, Grierson J, Kippax S. Marijuana as therapy for people living with HIV/AIDS: social and health aspects. AIDS Care. 2007;19(2):295–301.CrossRefPubMedGoogle Scholar
  20. 20.
    First MB, Spitzer RL, Gibbon M, Williams JBW. Structured clinical interview for DSM-IV axis I disorders, research version, patient/non-patient edition. New York: Biometrics Research, New York State Psychiatric Institute; 1996.Google Scholar
  21. 21.
    Mclellan AT, Kushner H, Metzger D, et al. The fifth edition of the addiction severity index. J Subst Abuse Treat. 1992;9(3):199–213.CrossRefPubMedGoogle Scholar
  22. 22.
    Sobell LC, Sobell MB. Timeline follow-back user’s guide: a calendar method for assessing alcohol and drug use. Toronto: Addiction Research Foundation; 1996.Google Scholar
  23. 23.
    Robinson SM, Sobell LC, Sobell MB, Leo GI. Reliability of the timeline followback for cocaine, cannabis, and cigarette use. Psychol Addict Behav. 2014;28(1):154–62.CrossRefPubMedGoogle Scholar
  24. 24.
    Simons J, Correia CJ, Carey KB, Borsari BE. Validating a five-factor marijuana motives measure: relations with use, problems, and alcohol motives. J Couns Psychol. 1998;45(3):265–73.CrossRefGoogle Scholar
  25. 25.
    Prentiss D, Power R, Balmas G, Tzuang G, Israelski DM. Patterns of marijuana use among patients with HIV/AIDS followed in a public health care setting. J Acquir Immune Defic Syndr. 2004;35(1):38–45.CrossRefPubMedGoogle Scholar
  26. 26.
    Corless IB, Lindgren T, Holzemer W, et al. Marijuana effectiveness as an HIV self-care strategy. Clin Nurs Res. 2009;18(2):172–93.CrossRefPubMedGoogle Scholar
  27. 27.
    Woolridge E, Barton S, Samuel J, Osorio J, Dougherty A, Holdcroft A. Cannabis use in HIV for pain and other medical symptoms. J Pain Symptom Manage. 2005;29(4):358–67.CrossRefPubMedGoogle Scholar
  28. 28.
    Nunberg H, Kilmer B, Pacula RL, Burgdorf J. An analysis of applicants presenting to a medical marijuana specialty practice in california. J Drug Policy Anal. 2011;4(1):1.PubMedPubMedCentralGoogle Scholar
  29. 29.
    Bonn-Miller MO, Boden MT, Bucossi MM, Babson KA. Self-reported cannabis use characteristics, patterns and helpfulness among medical cannabis users. Am J Drug Alcohol Abuse. 2014;40(1):23–30.CrossRefPubMedGoogle Scholar
  30. 30.
    Park JY, Wu LT. Prevalence, reasons, perceived effects, and correlates of medical marijuana use: a review. Drug Alcohol Depend. 2017;177:1–13.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Chabrol H, Beck C, Laconi S. Contribution of health motive to cannabis use among high-school students. Addict Behav. 2017;64:54–6.CrossRefPubMedGoogle Scholar
  32. 32.
    Ware JE, Kosinski M, Bjorner JB, Turner-Bowker DM, Gandek B, Maruish ME. User’s manual for the SF-36v2 health survey. 2nd ed. Lincoln: QualityMetric Incorporated; 2007.Google Scholar
  33. 33.
    Allshouse AA, MaWhinney S, Jankowski CM, Kohrt WM, Campbell TB, Erlandson KM. The impact of marijuana use on the successful aging of HIV-infected adults. J Acquir Immune Defic Syndr. 2015;69(2):187–92.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Hatsu I, Johnson P, Baum M, Huffman F, Thomlison B, Campa A. Association of supplemental nutrition assistance program (SNAP) with health related quality of life and disease state of HIV infected patients. AIDS Behav. 2014;18(11):2198–206.CrossRefPubMedGoogle Scholar
  35. 35.
    Henderson M, Safa F, Easterbrook P, Hotopf M. Fatigue among HIV-infected patients in the era of highly active antiretroviral therapy. HIV Med. 2005;6(5):347–52.CrossRefPubMedGoogle Scholar
  36. 36.
    Ware JE, Kosinski M, Dewey JE. How to score version 2 of the SF-36 health survey (Standard and Acute Forms). 2nd ed. Lincoln: QualityMetric, Inc.; 2000.Google Scholar
  37. 37.
    Sheehan DV, Lecrubier Y, Sheehan KH, et al. The mini international neuropsychiatric interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatr. 1998;59(Suppl 30):22–33.Google Scholar
  38. 38.
    Chabrol H, Duconge E, Casas C, Roura C, Carey KB. Relations between cannabis use and dependence, motives for cannabis use and anxious, depressive and borderline symptomatology. Addict Behav. 2005;30(4):829–40.CrossRefPubMedGoogle Scholar
  39. 39.
    Fox CL, Towe SL, Stephens RS, Walker DD, Roffman RA. Motives for cannabis use in high-risk adolescent users. Psychol Addict Behav. 2011;25(3):492–500.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Psychiatry and Behavioral SciencesDuke University School of MedicineDurhamUSA
  2. 2.Department of Psychology and NeuroscienceDuke UniversityDurhamUSA

Personalised recommendations